Clinical trial
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
NCT00124566 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00124566 |
|---|---|
| Title | Study of Irofulven in Patients With Hormone-refractory Prostate Cancer |
| Official title | Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Irofulven, Prednisone, Mitoxantrone, Capecitabine |
| Enrollment | 135 |
| Start date | Jun 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Dec 1, 2009 |
| First posted | Jul 28, 2005 |
| Last update posted | Jan 18, 2016 |
| Countries | Brazil, Canada, Chile, Croatia, France, Peru, Romania, Russia, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: